Graves’ Disease in Childhood and Pregnancy

by Elaine Moore

Patients with Graves’ disease have special concerns during pregnancy. For this reason, many doctors in the past have recommended that their patients have radioiodine ablation or surgery before becoming pregnant. With recent knowledge into the autoimmune nature of GD, it appears that this may not necessarily be the best solution for fetal health.

Patients who have become euthyroid or hypothyroid after these treatments are likely to still have high levels of thyroid antibodies, whereas patients who are treated with antithyroid drugs generally experience a significant reduction in their levels of thyroid antibodies.

These antibodies may cross the placental membrane causing transient hyperthyroidism or hypothyroidism in the fetus, depending on the type of antibody present. In patients who are considered “cured” fetal thyroid status is seldom assessed. Endocrinologists familiar with this problem recommend that these patients, especially those who have been treated with radioiodine in the past, have their thyroid antibody titers checked. They also recommend that the fetus be monitored for signs of thyroid dysfunction or goiter.

One type of thyroid antibody, the thyroid peroxidase (TPO) antibody is associated with spontaneous abortion or miscarriage.

Stimulating TSH receptor antibodies (also known as thyroid stimulating immunoglobulins or TSI) cause transient hyperthyroidism in the fetus and newborn, and blocking TSH receptor antibodies cause transient hypothyroidism.

Today, physicians are more likely to recommend antithyroid drugs (ATD’s) for their patients who plan to become pregnant in the future. Dr. Gregory Becks from St. Joseph’s Health Center in Ontario writes that it is essential to control the hyperthyroid state before proceeding with pregnancy.

While surgery and radioiodine generally work quicker, 40% of patients treated with radioiodine end up having more than one treatment, generally several months after the first. Although ATD’s take longer to achieve remission, most patients on ATD’s become euthyroid within the first 6 weeks of therapy. ♦

© 27 May 2006 Copyrighted by Elaine Moore 

Elaine Moore Graves' Disease and Autoimmune Disease Education 
Copyrighted by Elaine Moore. © All Rights Reserved 
Last updated: Oct 24, 2015

The pages and their content, including all articles and images, are copyrighted and are not to be copied, reproduced or printed without written permission. This site is self-funded exclusively by Elaine Moore. Moore has no other external sources of funds and receives no monies from government agencies, pharmaceutical companies or other commercial entities to operate this site. There are no conflicts of interest in the operation of this site. Books by Elaine Moore are promoted in the Books section. This site complies with the HONcode standard for trustworthy health information. Disclaimer: The information at this site about the benefits or performance of any diagnostic or treatment is supported by scientific evidence such as medical journals, reports, articles, and other relevant materials. The educational information provided within is designed to help users better understand the nature of disease and the solutions available. Nothing contained on this website should be construed as or is intended to be used for medical diagnosis or treatment. It is recommended that a physician be consulted for diagnostic testing and treatment. Reference to any specific commercial or noncommercial products, services, processes, companies or trademarks does not constitute an endorsement or recommendation. Elaine Moore does not host any form of commercial advertisement or sponsor or endorse any products or services mentioned at the site, excluding her own copyrighted materials, articles, and books. The opinions, views, and recommendations of those registered to this site, are their own and do not represent those of Elaine Moore.